Mikhail Blagosklonny is a scientist on the verge of impacting the world of medicine as we know it. He is also an oncology professor at the Roswell Park Cancer Institute in New York. Before his position at the Roswell Park Cancer, Blagoskloony was an associate professor of medicine at the New York Medical College in Valhalla, NY. Soon after, Blagoskloony was a senior scientist at Ordway Research Institute in Albany, NY until taking the position of oncology professor at Roswell.
His impressive educational background includes an M.D. in internal medicine and a PhD in experimental medicine and cardiology from First Pavlov State Medical University in St. Peterburg.
Mikhail Blagoskloony’s focus is cancer and aging. Specifically, his studies are of cancer treatments and therapies that avoid damaging healthy cells. He also studies the process of aging and the treatments and medicines to slow the process of aging down.
Through his research, Blagoskloony has devised the hypothesis that the cancer drug known as rapamycin can extend lifespan in humans. His research in the impact of TOR as an indicator of aging as well as cancer has lead him to his findings and hypothesis on the use of rapamycin in the use of longevity.
After successful conclusions with repeated experiments on mice, experiments will now be conducted on marmoset monkeys. Source: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531
With continued research, study, and experimentation, Mikhail Blagosklonny will discover whether or not his hypothesis is valid. The end result of this study and hypothesis has the potential to massively impact the human race in countless ways. One can only begin to imagine how life will change if humans are able to extend life, quality of life, and reduce the impact on healthy cells when using treatments.
Read more about Mikhail Blagosklonny Research Gate